Dr. Julie Xie is a seasoned executive with over 20 years of experience in the pharmaceutical and biotech industry, focusing on drug research and development. She currently is the head of Biology of Regor Pharmaceuticals. She has successfully led and delivered therapeutic programs from target identification through clinical development. Over the years of her career, she has been instrumental in developing R&D strategies and forming valuable alliances, including partnerships with academic institutions, biotech and global pharmaceutical companies. Most recently, she led the discovery and development of a portfolio of next-generation CDK inhibitors for treatment of breast cancer which was acquired by Roche Genentech in 2024. Dr. Xie earned her bachelor’s degree in Biochemistry from Wuhan University and Ph.D. in Biochemistry from University of Iowa. She completed her postdoctoral training in HHMI at Vanderbilt University.